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Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a member of the
ATP binding cassette (ABC) transporter superfamily that functions as a cAMP-activated
chloride ion channel in fluid-transporting epithelia. There is abundant evidence that
CFTR activity (i.e., channel opening and closing) is regulated by protein kinases and
phosphatases via phosphorylation and dephosphorylation. Here, we review recent
evidence for the role of protein kinases in regulation of CFTR delivery to and retention
in the plasma membrane. We review this information in a broader context of regulation of
other transporters by protein kinases because the overall functional output of transporters
involves the integrated control of both their number at the plasma membrane and their
specific activity. While many details of the regulation of intracellular distribution of CFTR
and other transporters remain to be elucidated, we hope that this review will motivate
research providing new insights into how protein kinases control membrane transport to
impact health and disease.
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CFTR ROLE IN HEALTH AND DISEASE
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein is a polytopic integral
membrane protein that functions as a cAMP- and phosphorylation-activated chloride (Cl−)
channel at the apical surface of secretory epithelia. CFTR is a member of the ATP-Binding
Cassette (ABC) transporter family, that hydrolyzes ATP to pump substrates, such as ions, vitamins,
drugs, toxins, and peptides across biological membranes (Riordan, 2008). Mutations in the
CFTR gene cause Cystic Fibrosis (CF), the most common autosomal recessive disorder among
Caucasians. At present, more than 2000 mutations have been identified while 127 are confirmed as
Abbreviations: AATYK2, apoptosis-associated tyrosine kinase; AMPK, AMP-dependent kinase; BREK, brain-enriched
kinase; cdk5, cyclin-dependent kinase-5; CF, Cystic fibrosis; CFTR, Cystic fibrosis transmembrane conductance regulator;
CK2, casein kinase 2; ENaC, epithelial sodium channel; HBE, human bronchial epithelial; LMTK2, Lemur tyrosine kinase;
MSD, membrane spanning domain; NBD, nucleotide binding domain; NCC, sodium-chloride co-transporter; OSR-1,
oxidative-stress-responsive kinase 1; PHA-II, pseudo-hypoaldosteronism type II; PKA, protein kinase A; PKC, protein kinase
C; Pyk, proline-rich tyrosine kinase; R, regulatory domain; KPI-2, kinase/phosphatase/inhibitor-2; ROMK1, renal outer
medullary potassium channel; SLC26A9, solute carrier 26A9; SPAK, STE20/SPS1-related, proline alanine-rich kinase; SYK,
spleen tyrosine kinase; TRPV, transient receptor potential cation channel subfamily V; WNK, with-no-lysine kinase.
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disease causing (Sosnay et al., 2013). Among these mutations,
deletion of phenylalanine at position 508 in the polypeptide
chain (F508del) is present in 85% of CF patients in at least one
allele. F508del causes the majority of mutant CFTR protein to
be retained in the endoplasmic reticulum (ER) with premature
degradation by the ubiquitin-proteasome system (Riordan,
2008).
Similarly to other ABC transporters, CFTR is composed of
two nucleotide-binding domains (NBD), involved in channel
regulation through ATP binding and hydrolysis, and two
membrane-spanning domains (MSD), that form the pore of the
channel. CFTR, however, is distinct in its structure as it possesses
a regulatory (R) domain that contains multiple phosphorylation
sites and a large proportion of charged amino acid residues
(Figure 1; Higgins, 1992a). This distinct structural feature makes
CFTR unique in the ABC transporter family and allows for tight
regulation of its Cl−-secretory activity (Higgins, 1992b; Riordan,
2008).
The overall flux of Cl− secretion through CFTR is the sum of
the activity of each individual CFTR channel and the number of
CFTR molecules present at the apical membrane. CFTR activity
depends on the intrinsic structure of the CFTR protein, on several
post-translational modifications, including phosphorylation, and
on the binding and hydrolysis of ATP at the NBDs. The number
of CFTR molecules at the PM results from a balance between
anterograde trafficking (through which CFTR is delivered from
the ER to the plasma membrane—PM), endocytosis (a process
through which CFTR is retrieved from the membrane into
vesicles), and recycling (with return of the internalized CFTR to
FIGURE 1 | CFTR structure and phosphorylation sites. CFTR possesses two membrane spanning domains (MSD1 and MSD2), two nucleotide biding domains
(NBD1 and NBD2), and the unique regulatory R domain.There are multiple phosphorylation sites in the R domain, but also in the NBD1 and in the C-terminus.
Phosphorylation of CFTR regulates its biogenesis, interaction with other proteins, trafficking, and function.
the PM). Both, the activity of individual channels and the channel
number at the PM are regulated by the interactions of CFTR with
multiple protein partners and by post-translational modification
(Sheppard et al., 1993; Zielenski, 2000; Wang and Linsdell, 2012).
CFTR BIOGENESIS AND TRAFFICKING
Like most membrane proteins entering the secretory pathway,
CFTR assembly begins with synthesis and folding in the
ER, where it is core-glycosylated (Cheng et al., 1990). Co-
translational folding of CFTR is an inefficient, slow, and complex
process whereby the nascent polypeptide is concomitantly folded
and inserted into the ER lipid bilayer (Farinha et al., 2002;
Glozman et al., 2009). During the co- and post-translational
folding, CFTR binds to several cytosolic and ER resident
molecular chaperones as well as ubiquitin ligase enzymes
(Meacham et al., 1999; Farinha et al., 2002). The glycans attached
to CFTR are also responsible for the interaction between the
protein and different lectins (in particular, calnexin), most of
which participate in the ER quality control (ERQC). At this stage,
misfolded CFTR is identified by the ERQC and degraded by
the ubiquitin-proteasome pathway (UPP; Amaral, 2005; Farinha
and Amaral, 2005). If correctly folded, CFTR proceeds to the
secretory pathway through the Golgi complex where it undergoes
further glycosylation and gradually attains its mature form. From
the TGN, CFTR traffics to the PMwhere its pool is maintained by
a balance between anterograde trafficking, endocytosis, recycling
to the membrane and lysosomal degradation (Ameen et al.,
2007).
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F508del-CFTR can also accumulate at the PM when
the trafficking defect is rescued by chemical, genetic, or
physical strategies (e.g., small molecule compounds, second-
site mutations, or low temperature, respectively; Amaral
and Farinha, 2013). However, rescued F508del-CFTR exhibits
defective channel gating—which can be partially due to defective
phosphorylation (Pasyk et al., 2015)—and decreased stability.
In fact, its biochemical half-life at the PM is about 4 h
compared to that of wt-CFTR that exceeds 48 h (Heda et al.,
2001). This instability is due to more rapid endocytosis of
mutant CFTR protein and/or its selective targeting for lysosomal
degradation (Swiatecka-Urban et al., 2005). Moreover, F508del-
CFTR recycling is attenuated by nearly five-fold as compared
with wt-CFTR, suggesting that misfolding of CFTR has also a
major impact on the sequestration of CFTR at the early endosome
(Sharma et al., 2004).
CFTR PHOSPHORYLATION IS NEEDED
FOR ITS CHANNEL ACTIVITY
CFTR channel function depends on the conformational changes
driven by ATP binding and hydrolysis at the heterodimer
NBD1:NBD2, shifting the molecule between the open and closed
states (Anderson et al., 1991). The transition in conformation
is however initiated by protein kinase A (PKA)-dependent
phosphorylation of the R domain. The open probability of the
channel is dependent on R domain phosphorylation at multiple
sites (Figure 1), reflecting a balance between protein kinase
and phosphatase activity (Cheng et al., 1991). Although CFTR
is primarily phosphorylated by PKA, other kinases have been
described to activate (cGMP-dependent protein kinase, Src, and
proline-rich tyrosine kinase Pyk2; Billet et al., 2015a,b), to inhibit
[AMP-dependent protein kinase (AMPK); Hallows et al., 2000],
or to have a dual effect on the channel activity [PKA and
protein kinase C (PKC); Jia et al., 1997; Chappe et al., 2004]
depending on the consensus site phosphorylated (Berger et al.,
1993; Alzamora et al., 2011). Among several phosphorylation
sites in the R domain, two in particular—S737 and S768—have
a phospho-dependent inhibitory effect on the CFTR channel
function (Wilkinson et al., 1997). Phosphorylation of these
inhibitory sites by AMPK inhibits CFTR mediated Cl− secretion
by maintaining the channel in a closed state (Kongsuphol et al.,
2009). Recent in vitrowork demonstrated that the S737 site is also
a preferred substrate for Lemur Tyrosine kinase (LMTK2; Wang
and Brautigan, 2006), as discussed below, but the tissue specificity
and hierarchy of the regulatory mechanisms involving either
AMPK or LMTK2 remain to be determined. In the following, we
will focus on recent evidence demonstrating how kinases regulate
CFTR biogenesis and trafficking, besides the well-characterized
role in activating CFTR, briefly described above.
CK2 AS A REGULATOR OF CFTR
BIOGENESIS AND FUNCTION
Casein Kinase II (CK2) is a ubiquitous, pleiotropic,
and constitutively active Ser/Thr protein kinase with a
heterotetrameric structure, where the holoenzyme contains two
α (catalytic) subunits offering the potential to simultaneously
phosphorylate different substrates. Additionally, CK2 has two
β regulatory, polyamine-binding subunits (Meggio and Pinna,
2003). CK2 is considered a master regulator that controls
protein expression, cell signaling, and ion channel activity by
coordinating the function of other kinases (Meggio and Pinna,
2003). CK2 has been reported to regulate protein trafficking at
multiple stages in the secretory pathway. Phosphorylation by
CK2 regulates the interaction of PM proteins with adaptors,
such as arrestins, thus controlling internalization of transporters
such as the Na+/H+ exchanger NHE5 and receptors, including
thyrotropin- and gonadotropin-releasing hormone receptors
(Hanyaloglu et al., 2001; Lukashova et al., 2011). The kinase has
also been reported to phosphorylate proteins involved in cell-
to-cell junctions, such as E-cadherin whose phosphorylation by
CK2 leads to its stabilization at the PM and to the strengthening
of adherens junctions in keratinocytes (Serres et al., 2000). In
addition, CK2 controls protein trafficking adaptors, as it has been
reported to phosphorylate Sec31, thus regulating the duration
of COPII vesicle formation, and p115, a vesicle-tethering
factor essential for ER-to-Golgi transport (Dirac-Svejstrup
et al., 2000; Koreishi et al., 2013). CK2 also regulates lysosomal
hydrolase trafficking and sorting of proteins in the transGolgi
network/endosomal system (Stockli et al., 2004; Scott et al.,
2006).
CK2 has been shown to regulate both CFTR biogenesis
and function (Treharne et al., 2009; Luz et al., 2011). The
co-localization of CK2 with wt-CFTR raised the possibility
that the kinase regulates CFTR channel function in apical
membranes of airway epithelial cells (Treharne et al., 2009).
This was confirmed by the finding that an inhibitor of CK2
attenuated CFTR-dependent Cl− transport in different model
systems, including mouse colon (Treharne et al., 2009; Luz et al.,
2011). This evidence was complemented with the in vitro CK2
phosphorylation of CFTR at S422 (Pagano et al., 2008). Although
several consensus sites for CK2 exist in CFTR, the region near
to F508 (namely the putative site S511) is not phosphorylated
by CK2. Instead, this CFTR region acts to allosterically control
both the isolated catalytic subunit and the holoenzyme of CK2
(Pagano et al., 2010). This was the first evidence demonstrating a
mutual CK2-CFTR interplay (Pagano et al., 2010). Specifically,
CK2 regulates the CFTR channel function, CK2 is modulated
by CFTR—being functionally perturbed by the F508del CFTR
mutation. Subsequently the close interplay between CFTR and
CK2 was confirmed by another study describing that CK2
inhibition reduced the difference between the phosphoproteome
resulting from the F508del CFTR gene mutation (Venerando
et al., 2011).
The role of CK2 in CFTR regulation was reinforced by
the observation that its pharmacological inhibition decreased
processing of wt-CFTR (Luz et al., 2011). This effect may
involve reduced phosphorylation of CFTR by CK2, previously
shown to occur at S422 (Pagano et al., 2008), or may occur
indirectly through other targets of CK2 that act as CFTR-
associated proteins. Another mechanism of regulation may occur
through phosphorylation of T1471 at CFTR C-terminus, a region
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involved in the control of multiple protein-protein interactions
that are critical for CFTR stability at the PM (Luz et al., 2011).
This T1471 site is homologous to T1467 in murine CFTR that
is readily phosphorylated by CK2 in vitro (Venerando et al.,
2013). Furthermore, a 42 amino acid peptide encompassing the
C-terminal segment of human CFTR is readily phosphorylated
at T1471 with favorable kinetics by the CK2 holoenzyme,
but neither by its isolated catalytic subunit nor by other
acidophilic Ser/Thr kinases such as CK1, PLK2/3, GCK/FAM20C
(Venerando et al., 2013). These putative CK2 phosphorylation
sites also impact the degradation pattern of CFTR—in fact,
cells generate endogenous CFTR fragments whose combined
fingerprint differs not only after F508 deletion, but also after
mutation of residues S511 and T1471 that are relevant to the
regulatory interactions of CFTRwith protein kinase CK2 (Tosoni
et al., 2013).
Recently, it was shown that CK2 inhibition is involved in the
mechanism through which epigallocatechin gallate (EGCG), a
green tea flavonoid, prolongs the rescue of F508del-CFTR PM
localization by cysteamine (De Stefano et al., 2014). This effect
was observed not only in cell lines but also in a mouse model
and in nasal cells from F508del-CFTR homozygous patients and
demonstrated for the first time that the kinase inhibition may
impact on the rescue of mutant CFTR (De Stefano et al., 2014).
In summary (Table 1), strong evidence exists that CK2
phosphorylates different sites in CFTR to control its function
and biogenesis. The CK2-CFTR interaction allows an allosteric
control of the kinase and regulates CFTR degradation, i.e.,
fragmentation pattern. The differential effect of wt- and F508del-
CFTR interplay with CK2 may provide an additional target for
modulation of CFTR trafficking and function in CF (Venerando
et al., 2011; De Stefano et al., 2014). The recent data that CK2
is a key player in the correction of the basic defect in patients
bearing the F508del mutation further strengthens this premise
(De Stefano et al., 2014).
SYK CONTROLS CFTR MEMBRANE
LEVELS
A second kinase that regulates CFTR trafficking is Spleen
Tyrosine Kinase (SYK). SYK is a cytoplasmic non-receptor
tyrosine kinase best known for its pro-inflammatory role in
immunoreceptor signaling in leukocytes (Mócsai et al., 2010).
SYK has been reported to phosphorylate CFTR at residue Y512
TABLE 1 | The CFTR-CK2 crosstalk.
CK2 modulates CFTR Promotes CFTR processing (Luz et al., 2011)
Promotes CFTR Cl− channel function (Treharne et al.,
2009)
Mediates F508del-CFTR rescue by cysteamine (De
Stefano et al., 2014)
Modulates CFTR degradation (Tosoni et al., 2013)
CFTR modulates CK2 Allosterically regulates CK2 activity (Pagano et al., 2008,
2010; Venerando et al., 2011, 2013)
leading to a decrease in PM levels of CFTR (Luz et al., 2011;
Mendes et al., 2011).
The first evidence linking CFTR and SYK suggested
possible functional interactions between SYK and CK2 in
regulating CFTR function. In particular, CK2 was found to
phosphorylate CFTR peptides corresponding to the sequence
PGTIKENIIFGVSY512DEYRYR only when residue Y512 was
substituted with phosphotyrosine, suggesting a hierarchical
interplay between the two kinases that requires priming
phosphorylation of CFTR Y512 by SYK, described both in vitro
and in vivo (Pagano et al., 2008, 2010; Luz et al., 2011; Mendes
et al., 2011).
Inhibition of SYK (or mutation of the potential SYK-
phosphorylation site in CFTR) was shown to strongly augment
Cl− currents in Xenopus oocytes, even those produced by
F508del-CFTR (Luz et al., 2011). The phosphorylation of Y512
is probably responsible for the interaction of SYK and CFTR
in human airway epithelial cells and leads to reduction in
CFTR at the PM. The effect was further demonstrated in CFTR
variants that mimic either a phosphorylated (Y512E) or non-
phosphorylated (Y512F) condition, with the former leading to
a reduction and the latter to an increase in the steady-state
levels of CFTR in the PM. However, the mechanistic details by
which SYK phosphorylation regulates CFTR levels in the PM
have not been elucidated. It is possible that SYK phosphorylation
of CFTR enhances its interaction with the kinase, as SYK contains
two SH2 domains (Mócsai et al., 2010). SH2 domains dock
to phosphorylated tyrosine residues on proteins (Mócsai et al.,
2010), and if SYK affects CFTR by such mechanism, the kinase
may function as an adaptor to regulate CFTR trafficking. It
remains unclear whether phosphorylation of Y512 can occur
through other kinases, as it was shown that the Src family kinase
Lyn phosphorylates this residue in a peptide encompassing CFTR
residues 500–523 in vitro (Cesaro et al., 2013).
Such a role of SYK in regulating protein trafficking has
been reported previously for other substrates. SYK can bind
through its SH2 domain to the phosphorylated form of the
membrane protein TGN38 and this association leads to increased
PM expression of TGN38, reinforcing that tyrosine-based motifs
may play a broader role in integrating trafficking and signaling
events (Stephens and Banting, 1997). Other data support a
role for SYK in the regulation of protein trafficking. For
example, SYK is essential for the trafficking of engaged high
affinity IgE receptor (FcεRI) to a degradative compartment in
mast cells. In this process, SYK phosphorylates the hepatocyte
growth factor-regulated tyrosine kinase substrate (Hrs), an
effector that functions as critical regulator for FcεRI entry into
lysosomes, providing an example on how SYK orchestrates
the crosstalk between endocytosis and signaling (Gasparrini
et al., 2012). Moreover, phosphorylated SYK recruits and
activates multiple downstream signaling molecules, including
the small GTPases Rac1 and Cdc42 (Greenberg, 1999), the
former of which was recently shown to play a role in
CFTR trafficking and membrane anchoring (Moniz et al.,
2013).
Current data show that phosphorylation of CFTR at Y512 by
SYK decreases the PM CFTR abundance. Thus, SYK inhibition
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may stabilize the PM wt-CFTR as well as the rescued F508del-
CFTR (Figure 2). SYK knockdown in airway epithelial cells
downregulates IL-6 and ICAM-1 (Ulanova et al., 2005). These
proinflammatory mediators are elevated in CF patients (Nixon
et al., 1998). Thus, SYK emerges as a potential target to stabilize
rescued mutant CFTR and attenuate the proinflammatory
mediators in CF.
WNKS CROSSTALK WITH SYK TO
REGULATE CFTR TRAFFICKING
The human subfamily of WNK (with-no-lysine) protein kinases
comprises four members, WNK1 through 4 (Veríssimo and
Jordan, 2001; Manning et al., 2002; Hanks, 2003), which regulate
the function and trafficking of different transporters. Mutations
in the WNK1 and WNK4 genes were initially discovered to
cause Gordon’s syndrome (or pseudo-hypoaldosteronism type
II, PHA-II), a rare familial form of hypertension (Wilson et al.,
2001) caused by renal salt retention. Subsequently, evidence has
been provided that WNK1 and WNK4 regulate the transport
activity of the renal co-transporter NCC by activating other
protein kinases, SPAK (STE20/SPS1-related, proline alanine-rich
kinase) or OSR-1 (Oxidative-stress-responsive kinase 1), which
in turn directly phosphorylate the N-terminal serine residues in
the co-transporters (Gamba, 2005; Kahle et al., 2008).
WNK kinases are co-expressed with CFTR in a variety of
tissues, including ciliated epithelial cells in the lung (Choate
et al., 2003; Yang et al., 2007). WNK1 and WNK4 inhibit
CFTR chloride channel activity in Xenopus oocytes, but the
mechanisms appear to be different as the two kinases exhibit
additive CFTR inhibition. The inhibitory effects of WNK1 are
kinase-dependent and do not affect CFTR abundance at the PM,
whereas the inhibitory effects of WNK4 are kinase-independent
and associated with a reduction in CFTR at the PM. In Xenopus
oocytes mutant WNK4 exhibits enhanced inhibition of CFTR
activity when compared to wt-WNK4 (Yang et al., 2007). This
is in agreement with the observation that PHA-II patients
with WNK4 mutations exhibit changes in epithelial potential
difference and conductance that resemble mild CF, which could
be explained by the ability of mutant WNK4 to suppress the the
epithelial sodium channel (ENaC) or CFTR in nasal epithelia and
sweat ducts of PHA-II patients (Farfel et al., 2005; Yang et al.,
2007).
The effects of WNK4 on CFTR activity are reminiscent
of the effects of WNK1, WNK3, and WNK4 on the activity
of the Cl−/HCO−3 exchanger SLC26A9 and of WNK1 and
WNK4 effects on the renal outer medullar potassium 1
(ROMK1) channel (Kahle et al., 2003; Lazrak et al., 2006;
He et al., 2007). The effects of different WNK kinases on
these three transporters are kinase-independent and associated
with a change in protein abundance at the PM. Therefore,
WNKs could act here as scaffolds that recruit other proteins
that regulate the activity and/or PM expression of these
channels. Such an effect was reported in a recent study in
renal distal convoluted tubule cells, where angiotensin II and
WNKs regulate the sodium-chloride co-transporter NCC in
a dual mode: a rapid response within 15min is mediated
by WNK4-dependent trafficking of NCC to the PM, but
sustained stimulation for over 60min activates WNK4/SPAK-
dependent NCC phosphorylation and transporter activation (Ko
et al., 2015). Similarly, WNK1 and WNK4 have been shown
to stimulate clathrin-dependent endocytosis of ROMK1, thus
inhibiting potassium secretion (Kahle et al., 2003; Cope et al.,
2006; Lazrak et al., 2006; He et al., 2007). A variety of other
reports described that WNKs also regulate PM abundance of a
variety of extra-renal ion transporters, including the potassium-
chloride co-transporter KCC, the transient receptor potential
cation (calcium) channel subfamily V members 4 and 5 (TRPV4
and TRPV5; Kahle et al., 2004, 2006, 2008; Gamba, 2005), and
ENaC.
FIGURE 2 | Proposed model for the role of SYK in regulating CFTR plasma membrane levels. (A) Activated SYK phosphorylates CFTR Y512 and triggers its
endocytosis. (B) WNK4 sequesters and inhibits SYK, thus stabilizing CFTR channels at the PM and increasing CFTR mediated Cl− transport (Mendes et al., 2011).
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Some mechanistic insights into how WNKs regulate PM
expression have been obtained. WNK4 inhibited the renal co-
transporter NCC (Cai et al., 2006; Subramanya et al., 2009) but
also the potassium channel Maxi K (Subramanya et al., 2009;
Zhuang et al., 2011) by redirecting the channels to lysosomal
degradation. For example, WNK4 associates with wt- as well
as Liddle’s mutated ENaC and enhances ENaC internalization
independent of Nedd4-2-mediated ENaC ubiquitination by an
unknown mechanism (Yu et al., 2013). WNK4 also inhibits
protein delivery and attenuates PM-targeting of NCC through
binding to syntaxin13 and inhibiting the SNARE complex
formation with VAMP2 in recycling and sorting endosomes
(Chung et al., 2013). In the case of TRPV5, WNK4 decreased
PM abundance of TRPV5 by enhancing its caveolin-mediated
endocytosis (Cha and Huang, 2010). Additional support
demonstrating the role of WNKs in endocytosis comes from a
genome-wide RNAi screen. In this screen, virus entry was used
to measure clathrin-mediated (vesicular stomatitis virus—VSV)
or caveolin-dependent (simian virus—SV40) endocytosis. It was
found that WNK4 interfered with the clathrin-mediated VSV
entry whereas WNK2 inhibited caveolin-mediated SV40 uptake
(Pelkmans et al., 2005). However, no further mechanistic details
were determined.
WNK4 was also shown to modulate the levels of CFTR at
the PM. In CFTR trafficking, WNK4 acts antagonistically to SYK
and promotes PM expression of CFTR (Figure 2). WNK kinases
are activated by changes in extracellular osmolarity (Kahle et al.,
2008). This regulatory mechanism may be used by WNK4 to
adjust CFTR function by sensing the osmolarity of the airway
surface liquid. This inhibition of SYK promoted byWNK4 seems
to be more dependent on its interaction with SYK rather than
a phosphorylation, as the inhibition is also observed with the
kinase dead WNK4 (Mendes et al., 2011). This is in agreement
with the inhibitory effects ofWNK4 on PMROMK1 (Kahle et al.,
2003) and EnaC (Ring et al., 2007). The antagonistic effects of
WNK4 and SYK on CFTRmay also involve endocytosis although
the mechanism has not been elucidated. If SYK phosphorylates
CFTR and triggers its endocytosis, WNK4 could sequester SYK
and increase retention of CFTR at the PM.
LMTK2 AS A REGULATOR OF CFTR
MEMBRANE LOCALIZATION AND
FUNCTION
The fourth protein kinase with a defined role in regulation of
CFTR trafficking and PM stability is Lemur Tyrosine Kinase
2 (LMTK2). LMTK2 is a member of the lemur family of
membrane-anchored kinases with multiple aliases such as
kinase/phosphatase/inhibitor-2 (KPI2), brain-enriched kinase
(BREK), apoptosis-associated tyrosine kinase (AATYK2),
or cyclin-dependent kinase-5 (cdk5/p35)-regulated kinase,
describing different functions and tissue localizations of the
protein. Despite the original prediction of a dual-specificity
serine-threonine/tyrosine kinase, biochemical studies have
shown that purified LMTK2 kinase domain phosphorylates
only serine and threonine, but not tyrosine residues (Wang
and Brautigan, 2002, 2006; Kawa et al., 2004). LMTK2 forms a
regulatory network with several cytosolic proteins via its long
C-terminal tail domain that prompted naming the protein
after the lemur, a long-tailed Madagascar primate (reviewed in
Rattray, 2012). The N-terminal transmembrane domain anchors
LMTK2 at the PM and is followed by the kinase domain (Wang
and Brautigan, 2002; Marchler-Bauer et al., 2003, 2013; Nixon
et al., 2013). The role of LMTK2 in intracellular trafficking was
first described in neuronal and muscle tissues (Lew et al., 1994;
Tsai et al., 1994; Fu et al., 2001; Chibalina et al., 2007; Inoue et al.,
2008; Manser et al., 2012). Subsequently, LMTK2 was shown to
facilitate endocytosis and decrease PM abundance of CFTR in
human bronchial epithelial (HBE) cells (Luz et al., 2014).
The site for CFTR phosphorylation by LMTK2 is the
inhibitory PKA/AMPK-site S737 (Wang and Brautigan, 2006).
In HBE cells, including primary differentiated HBE cells,
endogenous LMTK2 phosphorylates CFTR-S737, and decreases
CFTR mediated Cl− secretion by inducing endocytosis and
inhibiting PM accumulation of CFTR (Luz et al., 2014). The
authors presented several lines of evidence supporting these
conclusions. First, endogenous LMTK2 accumulated at the
apical PM of polarized HBE cells and co-immunoprecipitated
with CFTR, indicating that LMTK2 and CFTR physically
associate within this membrane domain. Next, inactivation
of LMTK2 by mutagenesis of the kinase domain reduced
phosphorylation of CFTR-S737 in HBE cells. Compared to
controls, LMTK2 knockdown by siRNA or substitution of
the LMTK2 phosphorylation site CFTR-S737 by a non-
phosphorylated residue increased the steady-state PM abundance
of CFTR and decreased its endocytosis. Conversely, inactivation
of the LMTK2 kinase by mutagenesis increased the steady-
state PM abundance of CFTR and decreased CFTR endocytosis
compared to control. LMTK2 also interacts with myosin
VI and together these proteins mediate endocytic trafficking
(Chibalina et al., 2007; Inoue et al., 2008; reviewed in Rattray,
2012). It had been shown that myosin VI facilitates CFTR
endocytosis (Swiatecka-Urban et al., 2004). Using truncated
LMTK2 proteins without the myosin VI binding domain or
the tail domain allowed the authors to demonstrate that
LMTK2 kinase specifically regulates the PM accumulation and
endocytosis of CFTR (Luz et al., 2014).
It remains unknown whether LMTK2 phosphorylation of
CFTR-S737 may also inhibit CFTR channel function in addition
to reducing the PM density of CFTR. Furthermore, the effects
of AMPK- and PKA-mediated phosphorylation of CFTR-S737
on the PM CFTR abundance are unknown. Hence, it remains to
be determined whether the phospho-dependent inhibitory effects
on CFTR-S737 are differentially mediated by each of the three
kinases, PKA, AMPK, and LMTK2 (Figure 3).
LMTK2 likely plays a physiologically relevant role in
regulating the inhibitory CFTR-S737 site in HBE cells because,
similar to mutagenesis of the S737 site, LMTK2 knockdown
produced a two-fold increase in the PM abundance of wt-
CFTR and a three-fold decrease in CFTR endocytosis. When
compared to the LMTK2 knockdown, the kinase-dead LMTK2
fragment produced lesser effect on the PM abundance and
endocytosis of CFTR, possibly because endogenous LMTK2
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FIGURE 3 | Phospho-dependent inhibitory effects of CFTR-S737 on CFTR mediated Cl− secretion. Serine-737 (S737) in CFTR regulatory (R) domain has a
phospho-dependent inhibitory effect on CFTR-mediated Cl− secretion. The PKA-mediated phosphorylation of S737 inhibits CFTR Cl− channel function. AMPK also
phosphorylates the S737 site and inhibits CFTR mediated Cl− secretion by maintaining CFTR channels in a closed state. This mechanism was proposed to play a role
in non-stimulated epithelia with high baseline AMPK activity (Kongsuphol et al., 2009). LMTK2 phosphorylation of S737 facilitates CFTR endocytosis, reduces the PM
density of CFTR Cl− channels, and ultimately reduces CFTR mediated Cl− secretion (Luz et al., 2014).
diminished the effects of the kinase deficient fragment when
compared to LMTK2 knockdown (Luz et al., 2014). It has been
proposed that AMPK activity is increased in non-stimulated
epithelia, leading to phosphorylation of S737, and inhibition
of CFTR channel function (Kongsuphol et al., 2009). Although
it is a plausible explanation, little data exist to support this
prediction. Similarly, increased activity of LMTK2 at the apical
PM was proposed to inhibit CFTR-mediated Cl− secretion at
least in part by attenuating the PM abundance of CFTR channels;
however, the mechanism through which LMTK2 activity is
regulated at the apical PM in HBE cells is unknown (Luz
et al., 2014). LMTK2 function can be affected by LMTK2 gene
polymorphisms or by protein kinase cdk5/p35, neither of which
are known to affect CFTR (Harries et al., 2010; Seo et al., 2012).
Mutations in the LMTK2 gene have also been associated with
lung adenocarcinoma in smokers (Seo et al., 2012), an interesting
observation since cigarette smoke is a negative regulator of
CFTR (reviewed in Rab et al., 2013). The mechanisms of CFTR
inhibition by cigarette smoke are incompletely defined so that
examining the effects of smoke exposure on LMTK2 activity may
increase our understanding of the environmental toxin’s effects
on CFTR function. Thus, far, it is unknown whether the CF
lung environment or CFmutations affect LMTK2 expression and
function.
LMTK2 knockdown increased CFTR mediated Cl− secretion
in cells expressing wt-CFTR (Luz et al., 2014). This effect was
also observed in cells expressing F508del-CFTR and correlated
with an increase in the amount of corrector VX-809-rescued
F508del-CFTR (mature band C). The effect of VX-809 was small
but similar to that observed in previous studies (Van Goor
et al., 2011; Cihil et al., 2013; Holleran et al., 2013). LMTK2
knockdown differentially affected the biochemical and functional
rescue of F508del-CFTR where a 10% increase in CFTR band
C abundance translated into a 50% rise of the forskolin/IBMX-
stimulated short-circuit current. Clinical studies have already
shown that targeted monotherapy with the CFTR correctors in
patients homozygous for F508del mutation is promising but still
inadequate, likely because of decreased function or reduced PM
stability of the pharmacologically-rescued F508del-CFTR (Van
Goor et al., 2011, 2014; Clancy et al., 2012; Molinski et al.,
2012). Hence, attenuating LMTK2 phosphorylation of F508del-
CFTR may play a role together with CFTR correctors and
potentiators to maximally rescue F508del-CFTR function in CF
patients. LMTK2 knockdown in immortalized HBE cells did
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not increase the steady-state abundance of partially glycosylated
F508del-CFTR band B and it did not rescue F508del-CFTR
in the absence of VX-809. These data suggest that the effects
of LMTK2 knockdown on CFTR in these cells were mediated
via alterations of post-maturational trafficking of CFTR during
endocytic uptake and not during the biosynthetic processing of
CFTR. It remains to be determined whether LMTK2 knockdown
has a similar effect in primary differentiated HBE cells.
In summary, published data support a model whereby
phosphorylation of S737 by PKA or AMPK closes CFTR
channels, while phosphorylation of S737 by LMTK2 reduces the
PM density of CFTR. More research is needed to determine
the specific contribution of the kinases to regulation of CFTR
function in different tissues and under different physiological and
disease states. Because rescued F508del-CFTR has decreased PM
stability, targeting LMTK2 phosphorylation of CFTR may offer
a novel approach to investigate the stability defect and to design
pharmacological approaches to stabilize rescued F508del-CFTR.
These findings may also point to a new direction in elucidating
the mechanisms of decreased CFTR function in lung diseases
resulting from cigarette smoke inhalation.
CONCLUSION
CFTR processing, trafficking, and activation are regulated
by multiple protein-protein interactions. While interactions
resulting in phosphorylation at the CFTR R domain regulate
channel opening, other interactions at the CFTR termini
modulate CFTR stability at the PM. For example, syntaxins
interact with the CFTR N-terminal tail and PDZ-proteins bind
to the PDZ-interacting domain at the CFTR C-terminal tail.
The multiprotein scaffolds anchor CFTR to the cytoskeleton
and allow CFTR to regulate other channels. Recent evidence,
reviewed here, has identified novel protein partners, including
the kinases CK2, SYK, WNK4, and LMTK2 regulating the
biogenesis, turnover, and trafficking of CFTR. Such evidence
increases our understanding of the complex CFTR interactome
and points to novel directions in search of additional therapeutic
targets to rescue F508del-CFTR and to increase the efficiency of
current generation CFTR modulators.
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